Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
about
The progress in the research of antiplatelet agents (1995-2017).Protease-activated receptor-4 and purinergic receptor P2Y12 dimerize, co-internalize, and activate Akt signaling via endosomal recruitment of β-arrestin.Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window.The platelet phenotype in patients with ST-segment elevation myocardial infarction is different from non-ST-segment elevation myocardial infarction.Perinatal lethality of Par4(-/-) mice delivered by primiparous dams reveals spontaneous bleeding in mice without platelet thrombin receptor function.The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis.PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation.PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy.Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy.Translational Implications of Platelets as Vascular First Responders.Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.Platelet Signaling Pathways and New Inhibitors.Protease activated receptor 4: a backup receptor or a dark horse as a target in antiplatelet therapy?On the article "Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window".Novel aspects of antiplatelet therapy in cardiovascular diseaseHematopoietic protease nexin-1 protects against lung injury by preventing thrombin signaling in miceAdvances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis
P2860
Q38669003-E32478BB-07C0-499F-B7E7-D03057019F95Q45012843-31211EDC-61C2-4FC2-BFE8-0CC328381F7CQ47107205-FA85FA56-908E-4CF3-ACE7-2D21B5569422Q47258737-D7268A80-AB6F-4FCA-914F-540F912B67DFQ47727892-82232F0E-BE11-4CF9-93C8-56D6F911E25EQ47950234-2C12F657-D6CF-4DD0-BAA9-E5EF94270EC3Q48560473-6737EC3E-DDED-4911-9AC4-7B0DB886E553Q49789909-F7925BF2-68E9-4CCB-B53D-FAFFB57CC455Q50002204-2D0EE7C5-4CD1-4168-99BE-00F4764D64D5Q50115928-027AE5D4-36FE-4A06-8B75-29A0E7B89BDFQ52568869-D2C0DE6D-1640-4717-B1A9-C76569A15340Q52644169-62F445D3-6502-44E1-818C-9F3DA400FF14Q55102493-7E1F6E68-A119-40AC-865A-6216BADEFC52Q55235008-6FEAE67E-5079-47D9-8ECE-76C08D938EBFQ57179203-D04CB158-2F60-4E82-A63C-675CB7E95787Q58698399-E03C91F9-D28C-4376-A743-5A42F05733C2Q58895615-8619EFE6-CD33-494E-A31A-DE4209BCF0C0
P2860
Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Blockade of protease-activated ...... ic activity with low bleeding.
@en
Blockade of protease-activated receptor-4
@nl
type
label
Blockade of protease-activated ...... ic activity with low bleeding.
@en
Blockade of protease-activated receptor-4
@nl
prefLabel
Blockade of protease-activated ...... ic activity with low bleeding.
@en
Blockade of protease-activated receptor-4
@nl
P2093
P2860
P1476
Blockade of protease-activated ...... ic activity with low bleeding.
@en
P2093
Anne Marinier
Brad D Maxwell
Carol A Watson
David A Gordon
David Harden
Dietmar Seiffert
E Scott Priestley
J Eileen Bird
Jacques Banville
Jeffrey S Bostwick
P2860
P356
10.1126/SCITRANSLMED.AAF5294
P407
P577
2017-01-01T00:00:00Z